- Home
- TEAF vs SGHT Comparison
TEAF vs SGHT Comparison
Compare TEAF & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- SGHT
- Stock Information
- Founded
- TEAF 2017
- SGHT 2011
- Country
- TEAF United States
- SGHT United States
- Employees
- TEAF N/A
- SGHT N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- SGHT Medical Specialities
- Sector
- TEAF Finance
- SGHT Health Care
- Exchange
- TEAF Nasdaq
- SGHT Nasdaq
- Market Cap
- TEAF 163.0M
- SGHT 179.7M
- IPO Year
- TEAF N/A
- SGHT 2021
- Fundamental
- Price
- TEAF $12.21
- SGHT $3.50
- Analyst Decision
- TEAF
- SGHT Buy
- Analyst Count
- TEAF 0
- SGHT 8
- Target Price
- TEAF N/A
- SGHT $3.87
- AVG Volume (30 Days)
- TEAF 56.1K
- SGHT 163.3K
- Earning Date
- TEAF 01-01-0001
- SGHT 07-31-2025
- Dividend Yield
- TEAF 9.20%
- SGHT N/A
- EPS Growth
- TEAF N/A
- SGHT N/A
- EPS
- TEAF N/A
- SGHT N/A
- Revenue
- TEAF N/A
- SGHT $78,109,000.00
- Revenue This Year
- TEAF N/A
- SGHT N/A
- Revenue Next Year
- TEAF N/A
- SGHT $11.22
- P/E Ratio
- TEAF N/A
- SGHT N/A
- Revenue Growth
- TEAF N/A
- SGHT N/A
- 52 Week Low
- TEAF $11.11
- SGHT $2.03
- 52 Week High
- TEAF $13.30
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- TEAF 58.26
- SGHT 43.79
- Support Level
- TEAF $12.13
- SGHT $3.34
- Resistance Level
- TEAF $12.23
- SGHT $3.65
- Average True Range (ATR)
- TEAF 0.10
- SGHT 0.25
- MACD
- TEAF -0.02
- SGHT -0.06
- Stochastic Oscillator
- TEAF 46.44
- SGHT 18.27
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a USA-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.